CN113795266A - 调节神经炎症 - Google Patents

调节神经炎症 Download PDF

Info

Publication number
CN113795266A
CN113795266A CN202080033681.5A CN202080033681A CN113795266A CN 113795266 A CN113795266 A CN 113795266A CN 202080033681 A CN202080033681 A CN 202080033681A CN 113795266 A CN113795266 A CN 113795266A
Authority
CN
China
Prior art keywords
hsp60
igfbpl1
administration
composition
hsp27
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080033681.5A
Other languages
English (en)
Chinese (zh)
Inventor
D.F.陈
K-S.乔
季敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN113795266A publication Critical patent/CN113795266A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080033681.5A 2019-03-04 2020-03-03 调节神经炎症 Pending CN113795266A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813556P 2019-03-04 2019-03-04
US62/813,556 2019-03-04
PCT/US2020/020794 WO2020180865A1 (en) 2019-03-04 2020-03-03 Modulating neuroinflammation

Publications (1)

Publication Number Publication Date
CN113795266A true CN113795266A (zh) 2021-12-14

Family

ID=72337602

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080033681.5A Pending CN113795266A (zh) 2019-03-04 2020-03-03 调节神经炎症

Country Status (7)

Country Link
US (1) US20220143139A1 (https=)
EP (1) EP3934674A4 (https=)
JP (2) JP7738377B2 (https=)
KR (1) KR20210148163A (https=)
CN (1) CN113795266A (https=)
CA (1) CA3132333A1 (https=)
WO (1) WO2020180865A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
KR102829678B1 (ko) * 2021-12-13 2025-07-04 차의과학대학교 산학협력단 신경전구세포를 포함하는 시신경병증의 예방 또는 치료용 약학 조성물
WO2024220474A1 (en) * 2023-04-21 2024-10-24 The Schepens Eye Research Institute, Inc. Methods of treating age-related macular degeneration targeting igfbpl-1
AU2024308069A1 (en) * 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
WO2007014323A2 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Use of heat shock to treat ocular disease
US20140128322A1 (en) * 2011-02-28 2014-05-08 Dong Feng Chen Compositions for Controlling Neuronal Outgrowth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529292A (ja) 2010-04-13 2013-07-18 エム−ラブ・アクチェンゲゼルシャフト 緑内障の診断方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
WO2007014323A2 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Use of heat shock to treat ocular disease
US20140128322A1 (en) * 2011-02-28 2014-05-08 Dong Feng Chen Compositions for Controlling Neuronal Outgrowth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERIC F.THEE ET AL.: ""Immune tolerance to HSP60 attenuatea neurodegeneration in a mouse model of glaucoma"", 《INVESTIGATIVE OPHTHALMOLOGY ＆ VISUAL SCIENCE》, vol. 59, 31 July 2018 (2018-07-31), pages 1 - 2 *
REILLY ET AL.: ""HspB1 (Hsp 27) Expression and Neuroprotection in the Retina"", 《MOL NEUROBIOL》, vol. 42, 2 June 2010 (2010-06-02), pages 124 - 132 *
XIN WEI ET AL.: ""A neuroprotective role of IGFBPL1 in glaucoma"", 《INVESTIGATIVE OPHTHALMOLOGY ＆ VISUAL SCIENCE》, vol. 59, 31 July 2018 (2018-07-31), pages 1 - 2 *

Also Published As

Publication number Publication date
EP3934674A1 (en) 2022-01-12
KR20210148163A (ko) 2021-12-07
CA3132333A1 (en) 2020-09-10
US20220143139A1 (en) 2022-05-12
WO2020180865A1 (en) 2020-09-10
JP2025087689A (ja) 2025-06-10
JP2022524325A (ja) 2022-05-02
EP3934674A4 (en) 2022-11-16
JP7738377B2 (ja) 2025-09-12

Similar Documents

Publication Publication Date Title
Ingwersen et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy
Jiang et al. Adaptive immunity: new aspects of pathogenesis underlying neurodegeneration in glaucoma and optic neuropathy
JP7738377B2 (ja) 神経炎症の調節
Lambiase et al. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases.
Dando et al. A case of mistaken identity: CD11c‐eYFP+ cells in the normal mouse brain parenchyma and neural retina display the phenotype of microglia, not dendritic cells
He et al. Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis
Liu et al. Overexpression of BMP4 protects retinal ganglion cells in a mouse model of experimental glaucoma
Vu et al. CD4+ T-cell responses mediate progressive neurodegeneration in experimental ischemic retinopathy
JP2015529685A (ja) 筋萎縮性側索硬化症の処置のための組成物および方法
US20210085749A1 (en) Therapeutic and Neuroprotective Peptides
Simon et al. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy
Schwartz Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders
EP2999479B1 (en) Human monocyte sub-population for treatment of eye diseases and disorders
JP2023521155A (ja) 網膜神経障害を予防及び治療するための方法及び組成物
US20210046002A1 (en) Amelioration of autoimmune uveitis through blockade of csf1r
Iwata et al. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-κB inhibitor dehydroxy methyl epoxyquinomicin in mice
US20250051458A1 (en) Methods for Treating Neurodegeneration Targeting IGF1/IGF1R
Adamus et al. Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice
US20230279086A1 (en) Suppression of uveitis by single domain antibody
Pan Neuroprotection through pharmacological targeting retinal immune microenvironment in retinal neurodegenerative diseases
RU2788097C2 (ru) Терапевтические и нейропротекторные пептиды
US9907763B2 (en) Method of treating or preventing the visual function loss by using 4-(phenylsulfanyl)butane-2-one (4-PSB-2)
Iwata Nuclear factor-κB inhibitor, dehydroxy methyl epoxyquinomicin, ameliorates
Pedreño Molina Neuroprotective and immunomodulatory roles of anti‐inflammatory neuropeptides on central nervous system disorders
Weiner et al. Microglia-Mediated Nitric Oxide Cytotoxicity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211214